- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Brand Name :
carbidopa
Synonyms :
Lodosyn
Class :
anti-parkinsonism and Decarboxylase Inhibitors
Dosage Forms & Strengths
Tablet
25 mg
carbidopa-levodopa treatment with additional carbidopa:
Initial dose: 25 mg orally once a day
Maintenance dose: additionally, 12.5 mg or 25 mg once a day
The duration of therapy is 200 mg orally per day
titration of carbidopa and levodopa:
Initial dose: 25 mg orally 3 to 4 times a day, levodopa given at the same time
The duration of therapy is 200 mg orally per day
may decrease the serum concentration and decrease in the efficacy
may decrease the therapeutic effect when combined with carbidopa
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
carbidopa concentrations serum could be reduced by spiramycin
carbidopa has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
May enhances the effects of the other by pharmacodynamic synergism
May enhances the effects of the other by pharmacodynamic synergism
may enhance the effects of the other by pharmacodynamic synergism
Adverse drug reactions:
Frequency not defined:
Agitation
Bruxism
Confusion
Dementia
depression with or without development of suicidal tendencies
Convulsions
Dizziness
burning sensation of the tongue
constipation
Pregnancy warnings:
AU TGA pregnancy category: B3
US FDA pregnancy category: C
Breastfeeding warnings:
The release of the drug into the human breastmilk is known
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits
Category X: Drugs listed in this category outweigh risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: carbidopa
Pronounced: KAR-bi-DOE-pa
Why do we use carbidopa?
carbidopa is an anti-parkinsonism drug belonging to the subclass Decarboxylase Inhibitors used to treat Parkinson’s disease. Carbidopa together taken with a drug levodopa to be effective.